- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03711292
Using Behavioral Science to Reduce Inappropriate Antibiotic Use in Acute Care Settings
Study Overview
Status
Intervention / Treatment
Detailed Description
Hypothesis: The primary hypothesis is that acute care ambulatory settings randomized to receive behavioral economic stewardship interventions will have decreased antibiotic prescribing rates for non-antibiotic appropriate ARIs, compared to contemporaneous antibiotic prescribing rates for non-antibiotic appropriate ARIs among control practices. This hypothesis will be evaluated in a linear mixed effects model will be used to estimate and test the group effect using group and time as fixed effects and practice site and provider as random effects. The interaction between time and group will be included to estimate and test the different group effect over time.
Design: The investigators will conduct a stepped wedge cluster randomized trial of acute care ambulatory visits to emergency departments and urgent care centers in a predominantly non-academic public hospital system. Clustering (by site) helps prevent treatment contamination between individual clinicians within the same site. The stepped wedge design will allow studying the effects of a complex intervention rolled out through a system over time, as often happens in the real-world, where State and Federal public health as well as site-based organization quality improvement interventions may be occurring at different times.
Treatment Assignment Procedures: For the 12-month intervention period, in a stepped-wedge fashion, sites will be exposed to a site-adapted multifaceted stewardship intervention consistent with Centers for Disease Control and Prevention (CDC) core elements for outpatient antimicrobial stewardship: commitment, action, monitoring, reporting and education, and also included a behavioral component that used individualized audit and feedback, peer comparison, and public commitment, in addition to standard patient and clinician education on antibiotic prescribing for antibiotic nonresponsive ARIs.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90012
- Department of Health Services
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
The primary research subjects involved in this trial are prescribing providers who will be recruited from multiple clinical sites in Los Angeles County Department of Health Services.
Eligibility (provider)
Inclusion Criteria:
* Prescribing provider in an adult emergency department or urgent care center in the Los Angeles County Department of Health Services.
Exclusion Criteria:
* Provider has not treated a patient with an ARI
Eligibility (patient)
Inclusion Criteria:
- Treated at a Los Angeles County Department of Health Services facility with an ARI diagnosis
- Cared for by a provider and in practice site enrolled in the study
- Visit occurred during the 12-month intervention period, or the 12-month historical baseline period
- Did not have a visit with any ARI diagnosis in the prior 30 days
Exclusion Criteria:
* None
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Stepped Wedge Cluster Randomized
Antibiotic stewardship intervention
|
For the 12-month intervention period, in a stepped-wedge fashion, sites will be exposed to a site-adapted multifaceted stewardship intervention consistent with CDC core elements for outpatient antimicrobial stewardship: commitment, action, monitoring, reporting and education, and also included a behavioral component that used individualized audit and feedback, peer comparison, and public commitment, in addition to standard patient and clinician education on antibiotic prescribing for antibiotic nonresponsive ARIs.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Antibiotic prescribing
Time Frame: 12 months
|
The primary outcome measure is the rate of antibiotic prescribing for non-antibiotic-appropriate acute respiratory infections or in other words, acute respiratory infections that are presumed to be viral in nature. The International Classification of Diseases (ICD)-10 codes for primary outcomes are defined in detail in the clinical trials protocol document. These outcomes are computable clinical quality measures from the electronic health record. These are widely used in medicine to evaluate quality improvement and reliability and validity are generally supported. Visits are excluded from the primary analysis when: 1) patients have certain medical co-morbidities that make ARI guidelines less likely to apply, 2) patients had concomitant visit diagnoses indicating a non-ARI possible bacterial infection, or 3) patients had concomitant visit diagnoses indicating potentially antibiotic appropriate ARI diagnoses or other ARI diagnoses suggestive of a bacterial infection. |
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diagnostic drift
Time Frame: 12 months
|
Throughout the course of the study, the investigators will also be monitoring "diagnostic drift" that may result in provider shifting diagnosis to avoid guideline conflicts that might trigger poor performance reports.
An auditing program will measure diagnostic deviation from each clinician's historical rates of diagnosing acute respiratory infections.
|
12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Kabir Yadav, MDCM MS MSHS, University of California, Los Angeles
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 31429-01
- UL1TR001881 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Upper Respiratory Infection
-
NovartisNovartis Consumer HealthCompleted
-
Daewon Pharmaceutical Co., Ltd.CompletedFever | Acute Upper Respiratory InfectionKorea, Republic of
-
Guangzhou Yipinhong Pharmaceutical CO.,LTDCompletedAcute Upper Respiratory InfectionChina
-
China Academy of Chinese Medical SciencesGuangdong Provincial Hospital of Traditional Chinese Medicine; Guang'anmen... and other collaboratorsUnknownAcute Upper Respiratory InfectionChina
-
Guangzhou Yipinhong Pharmaceutical CO.,LTDCompletedAcute Upper Respiratory InfectionChina
-
Société des Produits Nestlé (SPN)Completed
-
Penn State UniversityUniversity of GhanaNot yet recruitingUpper Resp Tract InfectionGhana
-
University of California, San FranciscoVapore, LLCWithdrawnAcute Upper Respiratory Infection | Signs and SymptomsUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownAcute Upper Respiratory Infection | Acute BronchitisKorea, Republic of
Clinical Trials on Antibiotic Stewardship
-
University Hospital, Basel, SwitzerlandUniversity of Bern; University Children's Hospital BaselCompletedUrinary Tract Infections | Acute Respiratory Tract InfectionSwitzerland
-
University Hospital of CologneCharite University, Berlin, Germany; University Hospital Tuebingen; University... and other collaboratorsCompletedClostridium Difficile Infection | Nosocomial Infection | VRE Infection | MRGN BacteriaGermany
-
Cees HertoghUniversity of Oslo; Göteborg University; UMC Utrecht; Medical University of Lodz; Vastra Gotaland RegionCompletedUrinary Tract InfectionsNetherlands, Norway, Poland, Sweden
-
UMC UtrechtCompletedCommunity-acquired PneumoniaNetherlands
-
Azienda Ospedaliera Universitaria Integrata VeronaAgenzia Italiana del FarmacoUnknownSurgical Site Infection | Antibiotic Resistant InfectionItaly
-
Chinese University of Hong KongNot yet recruiting
-
Brigham and Women's HospitalCenters for Disease Control and PreventionCompleted
-
Ostfold Hospital TrustCompleted
-
Children's Hospital of PhiladelphiaUniversity of Pennsylvania; Seattle Children's Hospital; Primary Children's Hospital and other collaboratorsActive, not recruitingPneumonia, Bacterial | Urinary Tract Infections | Soft Tissue Infections | Community-acquired Pneumonia | Pneumonia Childhood | Skin InfectionsUnited States
-
Central Hospital, Nancy, FranceNot yet recruitingHealthcare Associated Infection | Antibiotic